Financial statements March 31, 2023



Independent auditor's report

To the Board of Trustees of University Health Network

Opinion

We have audited the financial statements of the **University Health Network** ["UHN"], which comprise the statement of financial position as at March 31, 2023 and the statement of operations, statement of changes in net assets, statement of remeasurement gains and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of UHN as at March 31, 2023 and its results of operations and its cash flows for the year then ended in accordance with Canadian public sector accounting standards.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of UHN in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian public sector accounting standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing UHN's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate UHN or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing UHN's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of UHN's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on UHN's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause UHN to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business
 activities with UHN to express an opinion on the financial statements. We are responsible for the direction,
 supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Toronto, Canada June 16, 2023

Chartered Professional Accountants Licensed Public Accountants

Ernst & young LLP



Statement of financial position

[in thousands of dollars]

As at March 31

	2023	2022
	\$	\$
Assets Current		
Cash and cash equivalents [note 5[b]]	428,953	556,835
Accounts receivable [note 3]	420,953 358,326	353,037
Inventory	30,181	24,583
Prepaid expenses	25,610	33,515
Total current assets	843,070	967,970
Loans receivable	1,600	1.250
Capital assets, net [note 4]	1,607,137	1,474,057
Long-term investments	1,007,107	1,474,007
Held for contingency funds [note 5[a]]	15,083	52,611
Other [note 5[b]]	591,311	575,848
	3,058,201	3,071,736
Current Accounts payable and accrued liabilities [notes 3, 8[e], 13[a], 13[c] and 14[b]] Current portion of long-term liabilities [notes 6 and 8] Total current liabilities Due to MaRS Development Trust [note 6] Deferred research contributions [note 7] Long-term debt [note 8] Employee future benefit liabilities [note 9[b]] Deferred capital contributions [note 10] Total liabilities Commitments and contingencies [note 14]	1,099,434 4,930 1,104,364 57,975 450,152 143,785 52,449 700,815 2,509,540	1,113,354 28,643 1,141,997 61,443 419,564 108,447 53,069 691,367 2,475,887
Net assets From operations Internally restricted [note 11] Unrestricted	141,159 405,251 546,410	156,284 438,114 594,398
Accumulated remeasurement gains	2,251	1,451
Total net assets	548,661	595,849
	3,058,201	3,071,736

See accompanying notes

On behalf of the Board of Trustees:

Brian Porter

Chair, Board of Trustees

Stu Kedwell

Ata Keoluell

Chair, Finance and Audit Committee

Statement of operations

[in thousands of dollars]

Year ended March 31

	2023	2022
<u> </u>	\$	\$
Bayanya		
Revenue	4 070 774	4 700 000
Ontario Ministry of Health and Ontario Health	1,678,774	1,729,680
Other patient services	229,590	225,349
Grants and donations for research and other purposes [notes 7 and 13]	396,074	342,698
Ancillary services and other [notes 5[c] and 13[a]]	546,392	454,389
Amortization of deferred capital contributions [note 10]	63,925	66,336
	2,914,755	2,818,452
Expenses		
Compensation [notes 9 and 14]	1,791,037	1,640,611
Medical, surgical supplies and drugs	485,435	465,969
Other supplies and expenses [notes 13[b] and 13[c]]	384,706	405,185
Plant operations and equipment maintenance	156,819	154,918
Amortization of capital assets [note 4]	135,237	119,584
Interest on long-term liabilities [notes 6, 8[a], 8[b], 8[c] and 15]	9,509	23,407
	2,962,743	2,809,674
Excess (deficiency) of revenue over expenses for the year	(47,988)	8,778

Statement of changes in net assets

[in thousands of dollars]

Year ended March 31

		2023		2022
	Internally restricted	Unrestricted \$	Total \$	Total \$
Balance, beginning of year	156.284	438.114	594.398	585.620
Excess (deficiency) of revenue over expenses	,	(47,988)	(47,988)	8,778
for the year Interfund transfers [note 11]	— (15,125)	, ,	(47, 3 00) —	0,770 —
Balance, end of year	141,159	405,251	546,410	594,398

Statement of remeasurement gains

[in thousands of dollars]

Year ended March 31

	2023 \$	2022 \$
Accumulated remeasurement gains, beginning of year	1.451	734
Net unrealized gains (losses) attributable to	.,	
Interest rate swap contract [note 8[e]]	1,052	1,518
Portfolio investments	(252)	(801)
Accumulated remeasurement gains, end of year	2,251	1,451

Statement of cash flows

[in thousands of dollars]

Year ended March 31

Operating activities Excess (deficiency) of revenue over expenses for the year Add (deduct) items not involving cash Amortization Amortization of deferred capital contributions Other post-employment benefit expense 1,734 25,058 Net change in non-cash working capital balances related to operations [note 12[a]] Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net 21,813 Cash provided by (used in) investing activities Financing activities	\$ 8,778 119,584 (66,336) 1,481 63,507 326,653
Excess (deficiency) of revenue over expenses for the year Add (deduct) items not involving cash Amortization Amortization of deferred capital contributions Other post-employment benefit expense Net change in non-cash working capital balances related to operations [note 12[a]] Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities (47,988) (47,988) (47,988) (47,988) (63,925) (63,925) (19,734 (19,532) (19,532) (19,532) (19,532) (2,354) (2,354) (2,354) (2350)	119,584 (66,336) 1,481 63,507
Excess (deficiency) of revenue over expenses for the year Add (deduct) items not involving cash Amortization Amortization of deferred capital contributions Other post-employment benefit expense Net change in non-cash working capital balances related to operations [note 12[a]] Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities (47,988) (47,988) (47,988) (47,988) (63,925) (63,925) (19,734 (19,532) (19,532) (19,532) (19,532) (2,354) (2,354) (2,354) (2350)	119,584 (66,336) 1,481 63,507
Add (deduct) items not involving cash Amortization Amortization of deferred capital contributions Other post-employment benefit expense Net change in non-cash working capital balances related to operations [note 12[a]] Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 135,237 (63,925) (17,34 25,058 (19,532) (19,532) (19,532) (2,354) (2,354) (2,354) (350) Decrease (increase) in loans receivable, net 21,813 Cash provided by (used in) investing activities 21,463	119,584 (66,336) 1,481 63,507
Amortization of deferred capital contributions (63,925) Other post-employment benefit expense 1,734 25,058 Net change in non-cash working capital balances related to operations [note 12[a]] (19,532) Net increase in deferred research contributions 30,588 Employer contributions for employee benefit plan (2,354) Cash provided by operating activities 33,760 Investing activities Decrease (increase) in loans receivable, net (350) Decrease (increase) in other long-term investments, net 21,813 Cash provided by (used in) investing activities 21,463	(66,336) 1,481 63,507
Amortization of deferred capital contributions Other post-employment benefit expense 1,734 25,058 Net change in non-cash working capital balances related to operations [note 12[a]] (19,532) Net increase in deferred research contributions Employer contributions for employee benefit plan (2,354) Cash provided by operating activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 21,813 Cash provided by (used in) investing activities	(66,336) 1,481 63,507
Other post-employment benefit expense 1,734 25,058 Net change in non-cash working capital balances related to operations [note 12[a]] (19,532) Net increase in deferred research contributions 30,588 Employer contributions for employee benefit plan (2,354) Cash provided by operating activities 33,760 Investing activities Decrease (increase) in loans receivable, net (350) Decrease (increase) in other long-term investments, net 21,813 Cash provided by (used in) investing activities 21,463	1,481
Net change in non-cash working capital balances related to operations [note 12[a]] (19,532) Net increase in deferred research contributions 30,588 Employer contributions for employee benefit plan (2,354) Cash provided by operating activities 33,760 Investing activities Decrease (increase) in loans receivable, net (350) Decrease (increase) in other long-term investments, net 21,813 Cash provided by (used in) investing activities 21,463	63,507
Net change in non-cash working capital balances related to operations [note 12[a]] (19,532) Net increase in deferred research contributions 30,588 Employer contributions for employee benefit plan (2,354) Cash provided by operating activities 33,760 Investing activities Decrease (increase) in loans receivable, net (350) Decrease (increase) in other long-term investments, net 21,813 Cash provided by (used in) investing activities 21,463	
to operations [note 12[a]] Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Investing activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 21,463	326 653
Net increase in deferred research contributions Employer contributions for employee benefit plan Cash provided by operating activities Investing activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 21,813 21,463	320,033
Cash provided by operating activities Investing activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 33,760 (350) 21,813 21,463	64,998
Investing activities Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities (350) 21,813 21,463	(1,566)
Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities (350) 21,813 21,463	453,592
Decrease (increase) in loans receivable, net Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities (350) 21,813 21,463	
Decrease (increase) in other long-term investments, net Cash provided by (used in) investing activities 21,813 21,463	
Cash provided by (used in) investing activities 21,463	800
	(57,498)
Financing activities	(56,698)
· ····································	
Contributions received for capital purposes [note 12[b]] 73,373	57,266
Decrease in due to MaRS Development Trust (3,246)	(3,039)
Advances on long-term debt 36,800	84,500
Repayment of long-term debt (25,397)	(24,015)
Cash provided by financing activities 81,530	114,712
Capital activities	
Purchase of capital assets [note 12[b]] (264,635)	(227,290)
Cash used in capital activities (264,635)	(227,290)
Net increase (decrease) in cash during the year (127,882)	
Cash and cash equivalents, beginning of year 556,835	284,316
Cash and cash equivalents, end of year 428,953	284,316 272,519

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

1. Description of the organization

University Health Network ["UHN"] is a corporation without share capital incorporated under the *University Health Network Act, 2002*, devoted to patient care, education and research. UHN primarily fulfills its objects through the operation of four hospitals separately identified as the Princess Margaret Cancer Centre, the Toronto General Hospital, the Toronto Western Hospital and the Toronto Rehabilitation Institute.

As a charitable organization under the *Income Tax Act* (Canada), UHN is exempt from income taxes.

Under the *Health Insurance Act* (Ontario) and the regulations thereunder, UHN hospital operations are funded primarily by the Province of Ontario in accordance with funding arrangements established by the Ontario Ministry of Health ["MOH"], and Ontario Health.

2. Summary of significant accounting policies

These financial statements have been prepared in accordance with Canadian public sector accounting standards ["PSAS"] for government not-for-profit organizations as promulgated by CPA Canada. UHN has chosen to use the standards for government not-for-profit organizations that include Section PS 4200 to PS 4270. Accordingly, these financial statements have been prepared based on the significant accounting policies summarized below.

Basis of presentation

These financial statements include the assets, liabilities and results of operations of UHN for its activities at the four hospitals. These financial statements do not include the assets, liabilities or results of operations of the following non-controlled not-for-profit entities in which UHN has an economic interest [note 13]:

- UHN Foundation;
- Princess Margaret Cancer Foundation ["PMC Foundation"];
- The Toronto Hospital Research Corporation [inactive]; and
- de Souza Institute Foundation [inactive].

These financial statements do not include the assets, liabilities and results of operations of the entities controlled by UHN for which, in accordance with PSAS, UHN has chosen to disclose summarized information in a note [note 13].

Revenue recognition

UHN follows the deferral method of accounting for contributions. Contributions are recorded in the accounts when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Unrestricted contributions are recognized as revenue when initially recorded in the accounts. Externally restricted contributions are deferred when initially recorded in the accounts and recognized as revenue in the period in which the related expenses are incurred.

Revenue from ancillary services and other patient services is recognized when the goods have been sold or when the services have been rendered.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

Investment income (loss) recorded in the statement of operations consists of interest, dividends, income distributions from pooled funds, and realized gains and losses, net of related fees. Unrealized gains and losses are recorded in the statement of remeasurement gains.

Cash and cash equivalents

Cash and cash equivalents include cash on deposit and short-term investments that have a term to maturity of approximately three months or less from the date of purchase unless they are held for investment rather than liquidity purposes, in which case they are classified as long-term investments.

Inventory

Inventory is recorded at the lower of weighted average cost and current replacement value.

Capital assets

Purchased capital assets are recorded at cost. Donated capital assets are recorded at fair market value at the date of contribution. Capital assets are amortized on a straight-line basis at annual rates based on the estimated useful lives of the assets as follows:

Buildings and improvements 5–50 years Equipment and furniture 2–20 years Other equipment and systems 5–15 years

Assets leased on terms that transfer substantially all of the benefits and risks of ownership to UHN are accounted for as capital leases as though the asset had been purchased and a liability incurred. All other leases are accounted for as operating leases.

Assets under development comprises construction, development costs and interest capitalized during the construction period. Other equipment and systems includes hardware, software, development and other associated costs. No amortization is recorded until the assets are ready for productive use.

When a capital asset no longer has any long-term service potential to UHN, the excess of the carrying value over any residual value is recognized as an expense in the statement of operations.

Asset retirement obligations

Asset retirement obligations are recorded in the period during which a legal obligation associated with the retirement of a capital asset is incurred and when a reasonable estimate of this amount can be made. The asset retirement obligation is initially measured at the best estimate of the amount required to retire a capital asset at the financial statement date. A corresponding amount is added to the carrying amount of the related capital asset and is then amortized over its remaining useful life. Changes in the liability due to the passage of time are recognized as an accretion expense and are recorded within the accretion expense in the statement of operations, with a corresponding increase in the liability.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

The estimated amounts of future costs to retire the assets are reviewed annually and adjusted to reflect the then current best estimate of the liability. Adjustments may result from changes in the assumptions used to estimate the undiscounted cash flows required to settle the obligation, including changes in estimated probabilities, amounts and timing of settlement as well as changes in the legal requirements of the obligation, and in the discount rate. These changes are recognized as an increase or decrease in the carrying amount of the asset retirement obligation, with a corresponding adjustment to the carrying amount of the related asset. If the related capital asset is no longer in productive use, all subsequent changes in the estimate of the liability for asset retirement obligations are recognized as an expense in the period incurred.

UHN's asset retirement obligations are not significant to the financial statements.

Employee benefit plans

UHN accrues its obligations under employee benefit plans and the related costs. UHN has adopted the following policies:

Multi-employer plan

Defined contribution accounting is applied for the Healthcare of Ontario Pension Plan ["HOOPP"], a multi-employer pension plan, whereby contributions are expensed on an accrual basis.

Other defined benefit plans

The cost of non-pension post-employment and post-retirement benefits earned by employees is actuarially determined using the projected benefit method prorated on service and management's best estimate of retirement ages of employees and expected healthcare costs. The discount rate used to determine the accrued benefit obligation is determined by reference to UHN's cost of borrowing. Actuarial gains and losses are amortized over the average remaining service period of active employees, which is 16 years [2022 – 16 years]. Past service costs and settlement gains (losses) are recognized when incurred.

Financial instruments

Financial instruments are classified in one of the following categories: [i] fair value; or [ii] cost or amortized cost. UHN determines the classification of its financial instruments at initial recognition.

Financial instruments measured at fair value are classified according to a fair value hierarchy that reflects the importance of the data used to perform each valuation. The fair value hierarchy is made up of the following levels:

- Level 1 valuation based on quoted prices [unadjusted] in active markets for identical assets or liabilities;
- Level 2 valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly; and
- Level 3 valuation techniques using inputs for the asset or liability that are not based on observable market data [unobservable inputs].

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

Investments reported at fair value comprise equity instruments that are quoted in an active market as well as investments in pooled funds, derivative contracts and any other investments where the investments are managed on a fair value basis and the fair value option is elected. Transaction costs are recognized in the statement of operations in the period during which they are incurred. Investments at fair value are remeasured at their fair value at the end of each reporting period. Any revaluation gains and losses are recognized in the statement of remeasurement gains and are cumulatively reclassified to the statement of operations upon disposal or settlement.

Investments in securities not designated to be measured at fair value are initially recorded at fair value plus transaction costs and are subsequently measured at amortized cost using the effective interest rate method, less any provision for impairment.

All investment transactions are recorded on a trade date basis.

A write-down is recognized in the statement of operations for a portfolio investment in either category when there has been a loss in the value of the investment considered as an "other than temporary" loss. Subsequent changes to the remeasurement of portfolio investments in the fair value category are reported in the statement of remeasurement gains and losses. If the loss in value of a portfolio investment subsequently reverses, the write-down to the statement of operations is not reversed until the investment is sold.

Investments in for-profit entities that are subsidiaries or joint ventures, or where there is significant influence, are accounted for by the modified equity method. The modified equity method is a basis of accounting whereby the accounting principles of the invested entity are not modified to conform to those of UHN and inter-organizational transactions and balances are not eliminated except for gains and losses on assets remaining within UHN at the reporting date.

Long-term debt is initially recorded at fair value and subsequently measured at amortized cost using the effective interest rate method.

Other financial instruments, including cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities, are initially recorded at their fair value and are subsequently measured at cost, net of any provisions for impairment.

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Accounts requiring significant estimates include accounts receivable and the collectibility thereof, useful life of capital assets, accrued liabilities, deferred revenue, employee future benefits and asset retirement obligations.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

The amount of revenue recognized from the MOH and Ontario Health requires a number of estimates. UHN has entered into a number of accountability agreements with the MOH and Ontario Health that set out the rights and obligations of the two parties in respect of funding provided to UHN by the MOH and Ontario Health for the year ended March 31, 2023.

These accountability agreements set out certain performance standards and obligations that establish acceptable results for UHN's performance in a number of areas, such as margin, liquidity and operating volumes.

If UHN does not meet its performance standards or obligations, the MOH and Ontario Health have the right to adjust funding received by UHN. The MOH and Ontario Health are not required to communicate certain funding adjustments until after the submission of year-end data. Since this data is not submitted until after the completion of the financial statements, the amount of MOH and Ontario Health funding received during the year may be increased or decreased subsequent to year-end. The amount of revenue recognized in these financial statements represents management's best estimate of amounts that have been earned during the year.

Contributed services and materials

Volunteers contribute numerous hours to assist UHN in carrying out certain charitable aspects of its service delivery activities. The fair value of these contributed services is not readily determinable and, as such, they are not reflected in the financial statements. Contributed materials are also not recognized in the financial statements.

Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated into Canadian dollars at the exchange rate in effect at year-end. Revenue and expenses are translated at the average exchange rate prevailing on the transaction dates. Realized gains or losses arising from these foreign currency transactions are included in the statement of operations. Unrealized gains or losses are included in the statement of remeasurement gains, except to the extent they relate to amounts held for other organizations and deferred contributions, in which case they are added to the balances.

Adoption of new accounting standard

Effective April 1, 2022, UHN adopted the new accounting standard PS 3280, *Asset Retirement Obligations*, issued by the Canadian Public Sector Accounting Board. This standard provides guidance over the reporting of legal obligations associated with the retirement of capital assets that are either currently in productive use or no longer in productive use and controlled by the entity, and the costs associated with the retirement of these assets.

UHN's asset retirement obligations are not significant to the financial statements due to the immateriality of the balances. If the application of the new standard was reported, the following adjustments would have been made: capital assets increased by \$2,328, an asset retirement obligation created for \$10,055, opening net assets would have been reduced by \$7,122 and the excess (deficiency) of revenue over expenses for the year ending March 31, 2023 would be reduced by \$604 for the related accretion and amortization.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

3. Accounts receivable

Accounts receivable consist of the following:

	2023 \$	2022 \$
MOH and Ontario Health [see below]	130,845	149,766
Patient receivables	17,530	21,467
Other receivables	94,347	81,377
Michener [note 13[a]]	2,305	885
UHN Foundation [note 13[b]] PMC Foundation [note 13[c]]	28,772 37,016	27,871 37,862
Research-related receivables	47,511	33,809
	358,326	353,037

As at March 31, 2023, there is a provision against doubtful accounts of \$40,244 [2022 - \$35,144].

Operating under a memorandum of understanding with the MOH and Ontario Health, UHN purchased COVID-19 related supplies and equipment for flow through to various organizations. As at March 31, 2023, UHN had payables to the MOH of \$133,778 [2022 – payables of \$109,600], specifically related to COVID-19 purchases on behalf of the Province of Ontario.

4. Capital assets

Capital assets consist of the following:

	2023	
Cost	Accumulated amortization	Net book value
\$	\$	\$
18,573	_	18,573
2,148,310	1,152,389	995,921
1,245,777	1,045,272	200,505
152,222	7,611	144,611
247,527	_	247,527
3,812,409	2,205,272	1,607,137
	\$ 18,573 2,148,310 1,245,777 152,222 247,527	Accumulated amortization \$ \$ 18,573 — 2,148,310 1,152,389 1,245,777 1,045,272 152,222 7,611 247,527 —

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

		2022	
	Cost	Accumulated amortization	Net book value
	\$	\$	\$
Land	18,573	_	18,573
Buildings and improvements	2,059,299	1,079,687	979,612
Equipment and furniture	1,196,542	997,429	199,113
Other equipment and systems	64,796	_	64,796
Assets under development	211,963	_	211,963
	3,551,173	2,077,116	1,474,057

Buildings and improvements include \$88,329 [2022 – \$88,329] of costs and \$52,028 [2022 – \$49,083] of accumulated amortization related to assets under capital lease obligations *[note 6]*. During the year, UHN reduced the cost and accumulated amortization by \$7,081 [2022 – \$63] for capital assets that were fully amortized and no longer in use.

5. Long-term investments

[a] Long-term investments held for contingency funds are recorded at amortized cost and consist of the following:

	2023 \$	2022 \$
Short-term securities	12,531	10,734
Term deposits	2,552	23,850
Government bonds	_	8,857
Corporate bonds	_	9,170
	15,083	52,611

Long-term investments held for contingency funds are based on agreements with the MOH and bondholders.

One fund, with a restricted balance of \$25,000, was held to ensure patient services are not reduced due to financial pressures resulting from UHN's commitments to bondholders [note 8[a]]. UHN was also required to hold the equivalent of one semi-annual bond payment of \$12,528 in a segregated account known as the Debt Service Reserve Account until the bond was fully paid. The restrictions are now eliminated with the maturity of the 5.64% Secured Bonds on December 8, 2022.

The remaining segregated fund of \$15,083 has been established since 2004 to ensure patient services are not reduced due to financial pressures resulting from UHN's commitments to the MaRS Development Trust [the "MaRS Trust"] [note 6]. The fund will be terminated on the expiry of the 30-year term of the lease or earlier with the mutual agreement of the MOH and UHN.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

[b] Other long-term investments consist of the following:

	2023	2022
	\$	\$
Cash and cash equivalents	470,545	569,646
Fixed income [note 16]	60,773	440
Canadian equities [note 16]	16,975	_
Global equities [note 16]	20,666	_
Short-term securities [note 16]	19,095	1,924
Term deposits [note 16]	3,025	3,084
Government bonds [note 16]	· _	467
Other [note 5[d]]	232	287
	591,311	575,848

Cash and cash equivalents are included in other long-term investments to the extent required for investments to equal the total of deferred research contributions [note 7] and internally restricted net assets [note 11].

Investments held in pooled funds have been allocated among the asset classes based on the underlying investments in the pooled funds. Funds consist of equities, bonds and money market securities and are considered Level 2 investments for purposes of note 5 [e] below.

[c] During the year, UHN earned interest income of \$23,241 [2022 – \$4,966], which is included in ancillary services and other revenue in the statement of operations.

[d] Other investments

UHN has interests in various other companies as a result of research-related transactions, the value of which is recorded as other investments. Shares of other entities received as a result of research-related transactions had no cost or have been written down to nil.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

[e] The following table presents the investments measured at fair value [notes 5[a] and 5[b]] classified according to the fair value hierarchy described above:

	2023			
	Level 1	Level 2 \$	Level 3	Total assets at fair value
Fixed income	_	60,773	_	60,773
Canadian equities	_	16,975	_	16,975
Global equities	_	20,666	_	20,666
Short-term securities	12,531	19,095	_	31,626
Term deposits	5,577	_	_	5,577
Other	_	_	232	232
	18,108	117,509	232	135,849
Cash				470,545
Total investments				606,394

	2022			
	Level 1	Level 2 \$	Level 3	Total assets at fair value
Short-term securities	12,658	_	_	12,658
Term deposits	26,934	_		26,934
Government bonds	_	9,324		9,324
Corporate bonds	_	9,610	_	9,610
Other	_	_	287	287
	39,592	18,934	287	58,813
Cash				569,646
Total investments				628,459

During the years ended March 31, 2023 and 2022, there were no transfers of assets between Level 1, Level 2 and Level 3.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

6. Due to MaRS Development Trust

In 2003, UHN entered into a 30-year agreement with the MaRS Trust to lease a 400,000 square foot building, the Princess Margaret Cancer Research Tower. UHN is committed to an annual payment of \$7,541, which commenced on August 1, 2005, at an implicit interest rate of 6.7%. UHN recognized an obligation of \$100,000, consisting of a long-term capital lease obligation of \$88,329 representing the cost of the building to the MaRS Trust [note 4], and a further long-term obligation of \$11,671 representing cash received from the MaRS Trust related to financing proceeds in excess of the cost of the building and leasehold inducements. The obligation has been reduced by payments made since August 1, 2005, when payments commenced. During 2023, interest paid amounted to \$4,295 [2022 – \$4,503] and interest expense recorded in the statement of operations amounted to \$4,259 [2022 – \$4,469].

The future minimum annual payments related to the amount due to the MaRS Trust consist of the following:

	\$
2024	3,468
2025	3,706
2026	3,959
2027	4,229
2028	4,518
Thereafter	41,563
Due to MaRS Development Trust	61,443
Less current portion	3,468
	57,975

7. Deferred research contributions

Deferred research contributions represent unspent externally restricted grants and donations for research. The changes in the deferred research contributions balance are as follows:

	2023	2022
	\$	\$
Deferred research contributions, beginning of year	419,564	354,566
Externally restricted contributions [note 13]	426,662	407,696
Amounts recognized as revenue	(396,074)	(342,698)
Deferred research contributions, end of year	450,152	419,564

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

8. Long-term debt

Long-term debt consists of the following:

	2023 \$	2022 \$
5.64% Secured Bonds, Series 1 [note 8[a]]	_	24,022
Equity loan [note 8[b]]	550	619
Other loan [note 8[b]]	6,323	7,070
Obligation under Ontario Financing Authority loan [note 8[c]]	121,300	84,500
Drawing on credit facility [note 15]	17,074	17,633
	145,247	133,844
Less current portion	1,462	25,397
	143,785	108,447

- [a] On December 8, 1998, UHN issued \$281,000 of 5.64% Secured Bonds, Series 1 at a price of \$999. The Secured Bonds matured December 8, 2022. The bonds were secured with a first fixed charge on and assignment of substantially all cash receipts, book debts and monies of UHN and a floating charge on substantially all other property and assets of UHN, other than certain excluded assets such as funds held for research grants and donations included in deferred research contributions [note 7]. Blended semi-annual payments of principal and interest of \$12,528 commenced June 8, 2005 [note 5[a]]. During the year, interest paid amounted to \$1,021 [2022 \$2,322] and interest expense recorded in the statement of operations amounted to \$608 [2022 \$1,931].
- [b] Two loans were obtained to fund the construction of the long-term care facility operated by UHN: an equity loan of \$1,300 with a maturity date of 2029, bearing interest at 6.9% and blended monthly payments of principal and interest of \$9; and a \$14,200 loan with two agreements being amortized over periods ending in 2024 and 2034, bearing interest at a rate of 7.4% and blended monthly payments of principal and interest of \$104 to 2024 and \$64 to 2034. For the \$1,300 loan, UHN has pledged certain assets as security. For the \$14,200 loan, the following have been pledged as security: a debenture on a leasehold interest on the land related to the facility, an assignment of funds payable by the MOH for funding for construction and operation of the facility, an assignment of any insurance proceeds related to the facility, and all related buildings and equipment. During the year, interest paid amounted to \$541 [2022 \$599] and interest expense recorded in the statement of operations amounted to \$541 [2022 \$599].
- [c] On June 16, 2021, UHN secured a \$250,000 loan from the Ontario Financing Authority ["OFA"] to finance Synapse project a multi-year initiative of a new health information system. UHN established two facilities for the loan: Facility 1 and Facility 2. Facility 1 is a non-revolving loan facility comprising the advances made during the advance period up to the full facility amount. Principal amount plus the capitalized interest on the principal amount will be repaid on or before September 30, 2023 through Facility 2. Facility 1 is priced at the three-month Ontario Treasury Bill Rate plus 3.2 basis points. Facility 2 is a 40-year term loan and is priced at 2.758% plus 3.2 basis points compounded semi-annually and payable to the lender semi-annually commencing six months after the Facility 2 advance date. During 2023, interest [2022 interest and loan set-up fees] accrued amounted to \$3,282 [2022 \$15,564 interest paid] and interest [2022 interest and loan set-up fees] expense recorded in the statement of operations amounted to \$3,282 [2022 \$15,564]. Upon maturity, accrued interest on Facility 1 will be rolled into the principal for Facility 2 and amortized accordingly.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

[d] The future minimum annual payments related to the long-term debt consist of the following:

	<u> </u>
2024	1,462
2025	1,140
2026	1,122
2027	1,187
2028	1,256
Thereafter	139,080
	145,247

[e] On June 29, 2011, in order to manage the exposure to changes in interest rates on the demand bank indebtedness, UHN entered into a 30-year interest rate swap contract with a notional amount of \$22,000, an effective date of June 1, 2012, and a fixed interest rate of 4.36%. The fair value of the interest rate swap is a loss of \$1,450 [2022 – \$2,502] and is recorded in accounts payable and accrued liabilities in the statement of financial position. The change in the fair value of the interest rate swap is a gain of \$1,052 [2022 – \$1,518] recorded in the statement of remeasurement gains.

9. Employee benefit plans

UHN has a number of defined benefit plans and participates in a multi-employer plan providing pension, other retirement and post-employment benefits to most of its employees.

[a] Multi-employer plan

Substantially all of the employees of UHN are members of HOOPP, which is a multi-employer, defined benefit, final average earnings, contributory pension plan. HOOPP is accounted for as a defined contribution plan. UHN's contributions to HOOPP during the year amounted to \$91,436 [2022 – \$87,208]. These amounts are included in compensation expense in the statement of operations. The most recent valuation for financial reporting purposes completed by HOOPP as at December 31, 2022 disclosed net assets available for benefits of \$103,674,000 with pension obligations of \$92,721,000, resulting in a surplus of \$10,953,000.

[b] Other defined benefit plans

UHN offers various non-pension post-employment and post-retirement benefit plans to its employees that provide life insurance, medical and dental benefits. In addition, UHN offers a Supplemental Executive Retirement Plan ["SERP"] to certain employees. All of these plans are accounted for as defined benefit plans and are not funded by UHN.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

Information about UHN's other defined benefit plans is as follows:

	2023 \$	2022 \$
Accrued benefit obligations	44,130	46,356
Unamortized actuarial gain	8,319	6,713
Employee future benefit liabilities	52,449	53,069

The Employee future benefit liabilities include \$11,337 [2022 – \$11,597] related to the SERP.

The net expense for these plans is calculated as follows:

	2023 \$	2022 \$
Current service cost	714	1,442
Interest cost	1,680	1,512
Amortization of actuarial gains	(660)	(1,473)
	1,734	1,481

The significant actuarial assumptions adopted in measuring UHN's accrued benefit obligations are as follows:

	2023 %	2022 %
scount rate	4.60	3.70

The significant actuarial assumptions adopted in measuring UHN's expenses are as follows:

	2023 %	2022 %
Discount rate	3.70	3.10

Healthcare benefit costs are assumed to be 4.76% in 2023 and assumed to increase to 5.30% by 2026. Dental benefit costs are assumed to be 5.14% in 2023 and assumed to increase to 5.30% by 2026.

The accrued benefit obligations of the other defined benefit plans are measured as at March 31, 2023 and are based on actuarial valuations as at March 31, 2022.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

Other information about UHN's defined benefit plans is as follows:

	2023 \$	2022 \$
Employer's contributions	2,354	1,566
Benefits paid	2,354	1,566

10. Deferred capital contributions

Deferred capital contributions represent the unamortized amount of contributions received for the purchase of capital assets. The changes in the deferred capital contributions balance are as follows:

	2023 \$	2022 \$
Deferred capital contributions, beginning of year	691,367	700,437
Contributions for capital purposes [note 13]	73,373	57,266
Amortization of deferred capital contributions	(63,925)	(66,336)
Deferred capital contributions, end of year	700,815	691,367

As at March 31, 2023, the deferred capital contributions include funds received but not yet spent of \$34,709 [2022 – \$25,388].

11. Internally restricted net assets

Internally restricted net assets represent amounts set aside for future capital and other special projects.

Changes in internally restricted net assets, approved by the Board of Trustees, were as follows:

	2023 \$	2022 \$
Balance, beginning of year	156,284	164,585
Transfers from		
Internally restricted to unrestricted net assets	(109,881)	(83,202)
Unrestricted to internally restricted net assets	94,756	74,901
Balance, end of year	141,159	156,284

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

12. Supplemental cash flow information

[a] The net change in non-cash working capital balances related to operations consists of the following:

	_	2023 \$	2022 \$
	Accounts receivable	(5,289)	88,210
	Inventory	(5,598)	1,652
	Prepaid expenses	7,905	(4,293)
	Accounts payable and accrued liabilities [note 12[b]]	(16,550)	241,084
		(19,532)	326,653
[b]	Other information related to cash flows is as follows:		
		2023	2022
	<u> </u>	\$	\$
	Changes in capital asset purchases funded by accounts payable and		
	accrued liabilities	3,682	(901)

13. Related parties

Controlled entities

[a] UHN has two entities that it controls. Ozmosis Research Inc., which is a not-for-profit organization exempt from income taxes and was established to perform full service clinical trials management. Transactions between UHN and Ozmosis are not significant to these financial statements.

Michener is a tax-exempt charity, incorporated under the laws of Ontario. Michener is dedicated to the education of pre-eminent applied health science practitioners capable of providing transformational leadership, performance and evidence-based best practice. UHN exercises control over Michener through a governance structure.

The business relationship between UHN and Michener is governed by service agreements pursuant to which certain senior management support is provided on a cost recovery basis. For the year ended March 31, 2023, UHN recognized \$767 [2022 – \$2,726] in ancillary services and other revenue in the statement of operations. As at March 31, 2023, UHN has receivables from Michener of \$2,305 [2022 – \$885] recorded in accounts receivable *[note 3].*

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

Similar to UHN, Michener prepares its financial statements in accordance with PSAS for government not-for-profit organizations as promulgated by CPA Canada. Michener has chosen to use the standards for government not-for-profit organizations that include Section PS 4200 to PS 4270. The summarized assets, liabilities and results of operations for Michener as at and for the year ended March 31 are as follows:

\$ \$ [restated*] Financial position Total assets 51,238 40,554 Total liabilities 34,965 24,947 Net assets 16,273 15,607 St,238 40,554 2023 2022 \$ \$ Results of operations [restated*] Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967) Net increase in cash during the year 3,539 1,325		2023	2022
Financial position Total assets 51,238 40,554 Total liabilities 34,965 24,947 Net assets 16,273 15,607 51,238 40,554 Results of operations Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities 4,083 2,489 Investing activities 4,755 2,213 Capital activities 4,755 2,213 Capital activities (5,175) (2,967)		\$	\$
Total assets 51,238 40,554 Total liabilities 34,965 24,947 Net assets 16,273 15,607 51,238 40,554 Results of operations Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities 4,083 2,489 Investing activities 4,755 2,213 Capital activities 4,755 2,213 Capital activities (5,175) (2,967)			[restated*]
Total liabilities 34,965 24,947 Net assets 16,273 15,607		-1.000	10.554
Net assets 16,273 15,607 51,238 40,554 40,555	l otal assets	51,238	40,554
Results of operations Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 2023 2022 \$ \$ Cash flows provided by (used in) 2023 2022 Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)	Total liabilities	34,965	24,947
Results of operations [restated*] Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities 4,755 2,213 Capital activities 4,755 2,213 Capital activities (5,175) (2,967)	Net assets	16,273	15,607
Results of operations \$ [restated*] Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 2023 2022 \$ \$ Cash flows provided by (used in) 4,083 2,489 Investing activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)		51,238	40,554
\$ \$ Results of operations Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities 4,785 2,213 Capital activities 4,755 2,213 Capital activities (5,175) (2,967)		2023	2022
Results of operations Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)			
Total revenue 36,426 31,002 Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)		_	[restated*]
Total expenses 35,603 29,725 823 1,277 Cash flows provided by (used in) 2023 \$ Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)			
Cash flows provided by (used in) 2023 2022 Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)	Total revenue		
Cash flows provided by (used in) 2023 2022 Cash flows provided by (used in) 3 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)	Total expenses	35,603	
Cash flows provided by (used in) \$ \$ Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)		823	1,277
Cash flows provided by (used in) \$ Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)		2023	2022
Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)			\$
Operating activities 4,083 2,489 Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)	Cash flows provided by (used in)		
Investing activities (124) (410) Financing activities 4,755 2,213 Capital activities (5,175) (2,967)		4.083	2.489
Financing activities 4,755 2,213 Capital activities (5,175) (2,967)			
Capital activities (5,175) (2,967)		• •	
	-		
	·		

^{*}note: 2022 was restated for the implementation of the new asset retirement standards

Non-controlled entities

[b] The UHN Foundation is an independent corporation without share capital, which has its own Board of Directors. The UHN Foundation provides donations to UHN for capital, research and academic purposes. The UHN Foundation's accounts are not included in these financial statements. As at March 31, 2023, the UHN Foundation holds \$1,032,172 [2022 – \$931,527] in unrestricted, restricted and endowment funds. For the year ended March 31, 2023, grants of \$114,641 [2022 – \$105,076] were recorded by UHN as grants and donations for research and other purposes, deferred research contributions or deferred capital contributions. As at March 31, 2023, UHN has receivables from the UHN Foundation of \$28,722 [2022 – \$27,871] recorded in accounts receivable [note 3].

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

During the year ended March 31, 2023, UHN approved transfers of \$77,956 [2022 – \$64,257] to the UHN Foundation. As at March 31, 2023, UHN has payables to the UHN Foundation of \$78,166 [2022 – \$67,999] recorded in accounts payable and accrued liabilities.

[c] The PMC Foundation is an independent corporation without share capital, which has its own Board of Directors. The PMC Foundation provides donations to UHN for capital and operating purposes in connection with cancer research, education and treatment. The PMC Foundation's accounts are not included in these financial statements. As at March 31, 2023, the PMC Foundation holds \$801,172 [2022 – \$790,688] in unrestricted, restricted and endowment funds. For the year ended March 31, 2023, grants of \$144,882 [2022 – \$114,023] were recorded by UHN as grants and donations for research and other purposes, deferred contributions or deferred capital contributions. Effective October 22, 2019, PMC Foundation entered into a lease agreement with UHN for office space that expires on December 31, 2035.

During the year ended March 31, 2023, UHN approved transfers of \$1,626 [2022 – \$2,119] to the PMC Foundation. As at March 31, 2023, UHN has receivables from the PMC Foundation of \$37,016 [2022 – \$37,862] recorded in accounts receivable *[note 3]*. As at March 31, 2023, UHN had payables to the PMC Foundation of \$1,626 [2022 – \$8,873] recorded in accounts payable and accrued liabilities.

[d] The Toronto Hospital Research Corporation and the de Souza Institute Foundation are inactive.

14. Commitments and contingencies

- [a] UHN is subject to various claims and potential claims in connection with operations. Where the potential liability is able to be estimated, management believes that the ultimate disposition of the matters will not materially exceed the amounts recorded in the accounts. In other cases, the ultimate outcome of the claims cannot be determined at this time. Any additional losses related to claims will be recorded in the year during which the liability is able to be estimated or adjustments to the amount recorded are determined to be required.
- [b] UHN participates in the Healthcare Insurance Reciprocal of Canada ["HIROC"]. HIROC is a pooling of the public liability insurance risks of its hospital members. All members of the HIROC pool pay annual premiums, which are actuarially determined. All members are subject to assessment for losses, if any, experienced by the pool for the years in which they were members. No assessments have been made for the year ended March 31, 2023.
- [c] As at March 31, 2023, UHN's Board of Trustees have approved expenditures for construction and renovation of which \$254,853 [2022 \$151,903] has not been recorded in the accounts. Contracts have been entered into with respect to costs of \$78,887 [2022 \$60,665].
- [d] On November 8, 2019, the Ontario legislature passed Bill 124. The legislation imposed measures to cap compensation increases at 1% per year subject to certain exceptions. On November 29, 2022, Bill 124 was struck down by the Ontario Superior Court. Given the expectation of retroactive salary adjustments, UHN has included an accrual in accounts payable and accrued liabilities and an expense in compensation as at March 31, 2023.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

- [e] Effective March 31, 2006, UHN entered into an agreement with Plexxus, a not-for-profit shared services organization, whose primary responsibility is to provide materials management services to its members on a cost recovery basis and certain information technology services. The agreement with Plexxus was renewed on April 1, 2016 with an expiry date of March 31, 2021. Written notice of 24 months must be given after the expiry date in order to terminate the agreement. Based on the agreement, Plexxus has the right to charge membership fees to its members. A process is established in the agreement for Plexxus to obtain the approval of the members to charge additional fees. If any member fails to pay their membership fees to Plexxus throughout the period covered by the agreement, UHN and the other members are responsible for lending an amount to Plexxus, based on a sharing formula, to cover these deficiencies. As at March 31, 2023, no member is in default. Effective April 1, 2023, Plexxus amalgamated with Mohawk Medbuy. UHN has provided notice of their intent to terminate this agreement with Plexxus by March 31, 2024.
- [f] Commitments related to operating leases, including various operating costs and contracted utility services are as follows:

	\$
2024	37,057
2025	34,722
2026	34,832
2027	33,365
2028	31,801
Thereafter	720,057

[q] UHN has outstanding letters of credit to various organizations totalling \$100 [2022 – \$517].

15. Credit facilities

UHN has the following credit facilities:

- [a] A demand, revolving operating facility up to \$100,000 by way of a combination of prime rate loans, bankers' acceptances, and letters of credit to a maximum aggregate amount of \$10,000;
- [b] A demand, revolving amortizing credit facility up to \$80,000 by way of any combination of prime rate loans, bankers' acceptances, and fixed rate operating loans; and
- [c] A treasury risk management facility to hedge interest rate risk through interest rate swaps to a maximum notional risk amount of \$15,000 with a maximum term of 31 years.

For facilities [a] and [b], interest is payable at prime rate minus 0.55%, which is 6.15% as at March 31, 2023, or the bankers' acceptance rate plus 0.35%, which is 5.30% as at March 31, 2023. During the year, interest of \$819 [2022 – \$844] was paid and recorded in the statement of operations.

As at March 31, 2023, there are drawings on the second facility listed above of \$17,074 [2022 – \$17,633], which are classified as long-term as UHN has received confirmation from the lender that the lender will not require repayment in the next fiscal year *[note 8]*.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

16. Financial instruments and risk management

UHN is exposed to various financial risks through its transactions in financial instruments.

Credit risk

UHN is exposed to credit risk in connection with its accounts receivable and investments because of the risk that one party to the financial instrument may cause a financial loss for the other party by failing to discharge an obligation.

UHN manages and controls credit risk with respect to accounts receivable by dealing primarily with recognized, creditworthy third parties *[note 3]*. In addition, receivable balances are monitored on an ongoing basis.

The maximum exposure to credit risk relating to investments is outline in note 5. UHN manages credit risk for investments through an investment policy that establishes criteria for the selection of investments that include benchmarks for the creditworthiness of entities. UHN's investment policy specifies that no investments rated below investment grade by any of the rating agencies will be held, unless the original rating is likely to be restored within a reasonable period of time.

There have been no significant changes to credit risk exposure from 2022.

Liquidity risk

UHN is exposed to the risk that it will encounter difficulty in meeting obligations associated with its financial liabilities. UHN derives a significant portion of its operating revenue from the Ontario government and other funders with no firm commitment of funding in future years. To manage liquidity risk, UHN keeps sufficient resources readily available to meet its obligations. In addition, UHN has available lines of credit that are used when sufficient cash flow is not available from operations to cover operating and capital expenditures.

Accounts payable mature within six months. The maturities of other financial liabilities are provided in the notes to the financial statements related to these liabilities.

Interest rate risk

UHN is exposed to interest rate risk with respect to its investments in fixed income investments because the fair value will fluctuate due to changes in market interest rates. In addition, UHN is exposed to interest rate risk with respect to advances on its demand credit facilities because cash flows will fluctuate because the interest rate is linked to the bank's prime rate, which changes from time to time. UHN has entered into an interest rate swap contract to fix the rate of interest on its operating line of credit [note 8[e]].

UHN's investments in term deposits have an average term to maturity of seven months and an average yield of 3.91%, and for bonds an average term to maturity of four months and an average yield of 2.22%. A 1% change in the interest rates, with all other variables held constant, would have a \$436 impact on excess (deficiency) of revenue over expenses for the year.

Notes to financial statements

[all amounts are expressed in thousands of dollars, except where noted]

March 31, 2023

A change in the interest rate on UHN's long-term debt would have no impact on the financial statements since the debt is measured at amortized cost and has a fixed rate of interest. A change in the interest rate on the advance on the demand credit facility has no impact on excess (deficiency) of revenue over expenses for the year since UHN has entered into an interest rate swap contract to manage this risk.

There have been no significant changes to interest rate risk exposure from 2022.

Other price risk

UHN is exposed to other price risk through changes in market prices [other than changes arising from interest rate risk or currency risk] in connection with its investments in equity and pooled fund investment, whether those changes are caused by factors specific to the individual investment or factors affecting all securities traded in the market.

Since all other variables are held constant in assessing other price risk sensitivity, it is possible to extrapolate a 10% absolute change in the fair value to any absolute percentage change in fair value. As at March 31, 2023, the impact on accumulated remeasurement gains of a 10% absolute change in the fair value of the investments that are exposed to other price risk would be \$32,560 [2022 – \$456].

17. Comparative financial statements

The comparative financial statements have been reclassified from statements previously presented to conform to the presentation of the 2023 financial statements.